MDLifespan Company Profile

Background

Overview

MDLifespan is a physician-led medical technology startup specializing in toxin removal and regenerative wellness through its proprietary PlasmaXchange™ protocols. Founded by Dr. Paul Savage, the company is dedicated to addressing the health impacts of environmental toxins by offering advanced detoxification therapies. As a certified Public Benefit Corporation, MDLifespan emphasizes both financial success and public health benefits, aiming to reduce illness and enhance quality of life by eliminating environmental toxins.

Mission and Vision

• Mission: To develop and deliver innovative methods for eliminating environmental toxins from the human body, thereby reducing illness and disease, enhancing quality of life, and raising awareness about the existential threat toxins pose to humanity.

• Vision: To foster a society that prioritizes proactive care over pharmaceuticals, experiences fewer health problems, and enjoys richer lives, with a healthcare system that successfully helps healthy people stay healthy.

Industry Significance

MDLifespan operates within the burgeoning field of regenerative medicine, focusing on detoxification therapies to combat chronic diseases linked to environmental toxins. The company's innovative approach positions it as a leader in the $100+ billion personalized medicine market, addressing a critical need for effective detoxification solutions.

Key Strategic Focus

Core Objectives

• Toxin Removal: Utilize PlasmaXchange™ protocols to eliminate environmental toxins from the body, reducing chronic inflammation and associated health risks.

• Health Optimization: Enhance overall wellness by targeting the root causes of diseases through personalized detoxification therapies.

Areas of Specialization

• Therapeutic Plasma Exchange (TPE): Specialize in advanced TPE procedures designed to remove a wide range of toxins, including heavy metals, microplastics, pesticides, PFAS, mold toxins, and inflammatory proteins.

• Regenerative Wellness: Offer protocols aimed at rejuvenating bodily systems, supporting longevity, and improving quality of life.

Key Technologies Utilized

• PlasmaXchange™ Protocols: Proprietary TPE protocols that combine hospital-grade procedures with regenerative therapies to detoxify the body effectively.

• Advanced Diagnostics: Employ comprehensive testing to assess toxin levels and monitor health biomarkers, guiding personalized treatment plans.

Primary Markets Targeted

• Individuals Exposed to Environmental Toxins: Residents in areas with high pollution or industrial activity.

• Patients with Chronic Inflammatory Conditions: Individuals suffering from diseases linked to toxin exposure, such as neurodegenerative disorders, cardiovascular diseases, and autoimmune conditions.

Financials and Funding

Funding History

MDLifespan has secured early-stage health-tech investments to support its expansion and development of PlasmaXchange™ protocols. Specific details regarding total funds raised and notable investors are not publicly disclosed.

Recent Funding Rounds

The company has engaged in funding rounds to support its nationwide expansion and the scaling of its services. Details of these rounds, including amounts raised and investor identities, are not publicly available.

Utilization of Capital

The capital raised is intended for:

• Expansion of Treatment Centers: Opening new locations across the United States to increase accessibility to PlasmaXchange™ therapies.

• Research and Development: Enhancing and validating PlasmaXchange™ protocols through clinical studies and technological advancements.

• Marketing and Outreach: Educating the public and healthcare providers about the benefits of toxin removal and regenerative wellness.

Pipeline Development

Key Pipeline Candidates

• MDL Mold PlasmaXchange™ Protocol: A specialized protocol co-developed with Dr. Jill Carnahan, designed to remove up to 90% of mold toxins from the body, significantly outperforming traditional treatments.

• MDL Brain, MDL Heart, MDL Immunity, MDL Cancer, MDL Longevity, and MDL Toxins Protocols: Comprehensive detoxification protocols targeting specific health concerns associated with toxin exposure.

Stages of Development

MDLifespan's protocols are in active clinical use, with ongoing research to refine and validate their efficacy. The company continues to expand its services and gather clinical data to support the effectiveness of its treatments.

Target Conditions

• MDL Mold: Chronic mold toxicity.

• MDL Brain: Cognitive decline and neurodegenerative diseases.

• MDL Heart: Cardiovascular diseases.

• MDL Immunity: Immune system dysfunction and autoimmune conditions.

• MDL Cancer: Cancer prevention and post-recovery support.

• MDL Longevity: Aging and age-related health issues.

• MDL Toxins: General detoxification from environmental toxins.

Anticipated Milestones

• Expansion of Service Locations: Opening new treatment centers in additional states to broaden patient access.

• Clinical Validation: Publishing peer-reviewed studies demonstrating the efficacy of PlasmaXchange™ protocols in toxin removal and health optimization.

Technological Platform and Innovation

Proprietary Technologies

• PlasmaXchange™ Protocols: A patent-pending series of TPE procedures designed to remove a wide array of environmental toxins from the body, promoting health and longevity.

Significant Scientific Methods

• Therapeutic Plasma Exchange (TPE): A medical procedure where blood is passed through an apheresis machine, exchanging the plasma with a specialized solution, then returning the blood cells to the patient in the specialized solution. This process clears abnormal proteins and toxins from the body.

• Advanced Diagnostics: Utilizing comprehensive testing to assess toxin levels and monitor health biomarkers, guiding personalized treatment plans.

AI-Driven Capabilities

MDLifespan employs data-driven personalized medicine, using advanced diagnostics to assess toxin levels and track biomarker changes throughout the PlasmaXchange™ program, providing clear evidence of progress and supporting the journey to optimal health.

Leadership Team

Dr. Paul Savage – Founder and CEO

Dr. Savage is a pioneer in longevity medicine with over 25 years of experience. He has organized and launched over 50 clinics across the United States and developed industry-standard software that has helped millions of patients.

Dr. Moise Irizarry – Stem Cell Therapy Specialist

Dr. Irizarry specializes in stem cell therapy, focusing on regenerative treatments to promote healing and tissue regeneration.

Dr. Nikol Hopkins – Virtual Nutrition & Weight Loss Therapy Specialist

Dr. Hopkins provides virtual nutrition and weight loss therapy, offering personalized plans to support healthy weight management and nutritional balance.

Dr. Peter Schulz – Chiropractic Medicine Specialist

Dr. Schulz offers chiropractic care, focusing on spinal health and its impact on overall well-being.

Dr. Gertrude Lyons – Virtual Life Coaching Specialist

Dr. Lyons provides virtual life coaching, assisting individuals in achieving personal and professional goals through guided support.

Joey Thurman – Virtual Fitness Training Specialist

Joey Thurman offers virtual fitness training, creating customized exercise programs to enhance physical health and fitness.

Leadership Changes

As of February 2026, there have been no publicly disclosed significant changes or appointments within MDLifespan's leadership team.

Competitor Profile

Market Insights and Dynamics

The personalized medicine market, particularly in the realm of detoxification and regenerative wellness, is experiencing significant growth. Environmental toxins are increasingly recognized as contributors to chronic diseases, driving demand for effective detoxification therapies.

Competitor Analysis

• Cenegenics: A global provider of age-management and performance health medicine, offering services that may overlap with MDLifespan's offerings.

Strategic Collaborations and Partnerships

• Cenegenics Partnership: In January 2026, MDLifespan entered into a strategic partnership with Cenegenics to expand access to Therapeutic Plasma Exchange (TPE) across the United States.

Operational Insights

MDLifespan differentiates itself by focusing exclusively on TPE for toxin removal, backed by a team of experts dedicated to this specialized field. This singular focus allows for a depth of expertise and a commitment to advancing detoxification therapies.